In HNSCC, neoadjuvant combined anti-PD-1 and anti-CTLA-4 ICB lead to a major pathological response (MPR) in 20–35% of patients [6, 7]. The gene discussed is CTLA4; the disease is head and neck squamous cell carcinoma.